Research map: Insights Into Genomic Drivers, Transcriptomic Heterogeneity, and Therapeutic Vulnerabilities From Novel Mesothelioma Cell Lines

Back to the article

Papers in this map

  1. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features · Yang Liao · 2013 · 30442 citations · Cited by this paper
  2. Histone Variant H2A . Z2 Hyper‐Transcription Induced by E2F1 Accelerates Lung Adenocarcinoma Progression via the JAK – STAT Signaling Pathway · 2026 · Related
  3. Adjusting batch effects in microarray expression data using empirical Bayes methods · William Evan Johnson · 2006 · 9427 citations · Cited by this paper
  4. Synchronous Surgical Therapy for Bilateral Multiple Pulmonary Nodules: A Single‐Center Analysis of 108 Cases · 2026 · Related
  5. The sva package for removing batch effects and other unwanted variation in high-throughput experiments · Jeffrey T. Leek · 2012 · 6929 citations · Cited by this paper
  6. Importance of Multimodal Testing for Novel ALK Fusions: A Case of MTHFD1L‐ALK Positive Lung Squamous Cell Carcinoma With Negative IHC · 2026 · Related
  7. Maftools: efficient and comprehensive analysis of somatic variants in cancer · Anand Mayakonda · 2018 · 5596 citations · Cited by this paper
  8. Association Between Osimertinib Dose Reduction and Treatment Outcomes in First‐Line EGFR ‐Mutated Advanced NSCLC : The Impact of Post‐Progression Management · 2026 · Related
  9. Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model · Bhagwan Yadav · 2015 · 910 citations · Cited by this paper
  10. Incidence Patterns and Prognostic Impact of Lung‐Involving Multiple Primary Cancers: A 10‐Year Hospital‐Based Cohort Study · 2026 · Related
  11. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples · Aleksandr Ianevski · 2022 · 815 citations · Cited by this paper
  12. Association Between Treatment Sequencing and Overall Survival in Stage IV NSCLC With Brain Metastases: A National Cancer Database Study · 2026 · Related
  13. Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin · Paolo Andrea Zucali · 2011 · 101 citations · Cited by this paper
  14. First‐Line Alectinib Versus Ceritinib With or Without Brain Radiotherapy in ALK ‐Positive Non‐Small Cell Lung Cancer with Brain Metastases: A Real‐World Multicenter Study from Vietnam · 2026 · Related
  15. A Combination of Species Identification and STR Profiling Identifies Cross-contaminated Cells from 482 Human Tumor Cell Lines · Xiaocui Bian · 2017 · 85 citations · Cited by this paper
  16. Advanced Thymoma and Advanced Thymic Carcinoma Treatment Practices in 2018–2022: A Nationwide Analysis in Japan · 2026 · Related
  17. Treatment of Pleural Mesothelioma: ASCO Guideline Update · Hedy Lee Kindler · 2025 · 59 citations · Cited by this paper
  18. Multi‐Omics Analysis Reveals Differentially Expressed Proteins and Metabolites in Malignant Pleural Effusion · 2026 · Related
  19. Establishment of human malignant mesothelioma cell lines · Marjan A. Versnel · 1989 · 52 citations · Cited by this paper
  20. Case Report: Rare Peripheral Neuropathy With Abdominal Wall Allodynia in Extensive‐Stage Small‐Cell Lung Cancer Treated Using Durvalumab · 2026 · Related
  21. Pirfenidone decreases mesothelioma cell proliferation and migration via inhibition of ERK and AKT and regulates mesothelioma tumor microenvironment in vivo · Chang Li · 2018 · 47 citations · Cited by this paper
  22. Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study · Luana Calabrò · 2021 · 46 citations · Cited by this paper
  23. Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma—RIOMeso · Nicholas McNamee · 2023 · 37 citations · Cited by this paper
  24. Use of preclinical models for malignant pleural mesothelioma · Marie Shamseddin · 2021 · 33 citations · Cited by this paper
  25. Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress · Matteo Perrino · 2023 · 29 citations · Cited by this paper
  26. Establishment of permanent cell lines purified from human mesothelioma: morphological aspects, new marker expression and karyotypic analysis · Marie-Marthe Philippeaux · 2004 · 23 citations · Cited by this paper
  27. BAP1 Deficiency Inflames the Tumor Immune Microenvironment and Is a Candidate Biomarker for Immunotherapy Response in Malignant Pleural Mesothelioma · Duo Xu · 2024 · 15 citations · Cited by this paper
  28. Patient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatments · Nikolaos I. Kanellakis · 2020 · 12 citations · Cited by this paper
  29. Untitled · Cited by this paper
  30. Untitled · Cited by this paper
  31. Untitled · Cited by this paper
  32. Untitled · Cited by this paper

Source: OpenAlex (CC0)